fbpx
Healthtech

Heart disease diagnostic startup ESN Cleer raises $700,000 as the medtech hits commercialisation

- April 23, 2021 < 1 MIN READ
ESN Cleer's executive team: COO Johnny Feng, CEO Leo de Bruin and CIO Gustav de Bruin. Photo: supplied
Melbourne-based ESN Cleer says it’s now just months away from delivering a major medical breakthrough – the world’s first early risk detection screening test for heart disease – after raising $650,000 via crowd-funding site VentureCrowd. The raise was topped up by another $50,000 direct investment.

The medtech startup has developed a simple saliva test that can be used by GPs to detect early risk for developing heart failure, which kills 10 million people annually. The technology ESN Cleer developed has a 95% accuracy rate for early detection.

The startup uses patent protected biomarkers and nano-technology to detect heart failure risk. It’s two main products, EHF-Test Kit and EHF-Eswab are expecting US FDA approval in 2021, and 2022 respectively.

The crowdfunding cash will go towards distribution and implementing a wider go-to-market strategy. The company previously raised nearly $200,000 through Birchal late last year.

ESN Cleer’s CEO and Managing Director, Leo de Bruijn said the saliva test provides people at risk of heart failure with the chance to implement lifestyle changes and medical interventions to reduce those risks.

“With protected IP sitting behind the technology and pre-sales for our devices due to launch in the coming months, we anticipate our fundraise via VentureCrowd will support us to achieve a strong return on investment over the course of the next two years,” he said.

Pre-orders for testing kits will be taken via cleer.com.au in mid-May for less than A$100.